

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

ANNOUNCEMENT IN RELATION TO THE RESIGNATION OF A SUPERVISOR AND PROPOSED APPOINTMENT OF A SUPERVISOR

This announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

THE RESIGNATION OF A SUPERVISOR

The Board was notified by the Company’s supervisory committee (the “**Supervisory Committee**”) that, Mr. Cai Ruiyu (“**Mr. Cai**”), chairperson of the Supervisory Committee resigned from his position as chairperson of the Company’s 9th session of the Supervisory Committee and as the supervisor representing shareholders of the Company due to professional career changes.

In accordance with the relevant provisions of the Company Law of the People’s Republic of China and the Company’s articles of association, Mr. Cai’s resignation will not take effect until a new supervisor has been elected, as the resignation will result in the number of supervisors on the Supervisory Committee being reduced to fewer than three.

Mr. Cai confirmed that he had no disagreements with the Board and the Supervisory Committee, and there were no matters relating to his resignation that needed to be brought to the attention of the shareholders of the Company.

PROPOSED APPOINTMENT OF A SUPERVISOR

The Company hereby announces that at the 10th meeting of the 9th session of the Supervisory Committee held on 24 December 2024, Ms. Liu Lan (“**Ms. Liu**”) was nominated as a candidate for the position of supervisor representing shareholders.

The biographical details of Ms. Liu are set out below:

Ms. Liu Lan, aged 46, holds a master's degree of Economic Law and a doctoral degree of management. She is a senior intellectual property engineer, legal counsel of a state-owned enterprise and a corporate legal counsel. Ms. Liu started her career in July 2004, and has successively served as the head of the legal affairs department (integrated management), general counsel of the legal affairs department (corporate strategies) and deputy manager of Guangdong Telecom Company Limited (廣東省電信有限公司), deputy general manager and general manager of the legal affairs centre of Guangdong branch of China Telecom Co., Ltd. (中國電信股份有限公司廣東分公司). Ms. Liu is the deputy officer of legal affairs of Guangzhou Pharmaceutical Holdings Limited (廣州醫藥集團有限公司), and a director of Guangzhou Chuangying Guangyao Baiyunshan Intellectual Property Co., Ltd. (廣州創贏廣藥白雲山知識產權有限公司) and Guangzhou Pharmaceuticals Company Limited (廣州醫藥股份有限公司). Ms. Liu has been the deputy officer of legal affairs of the Company since April 2022. Ms. Liu has extensive experience in the areas of intellectual properties, compliance management, legal affairs, corporate governance and risk prevention.

Upon approval of Ms. Liu appointment by the shareholders, the Company will enter into a service contract with Ms. Liu for a term commencing from the date of approval by the shareholders at the general meeting till the expiry of the tenure of the 9th session of the Supervisory Committee of the Company. Pursuant to the articles of the association of the Company, Ms. Liu is eligible for re-election upon the expiry of her term of office.

Ms. Liu's remuneration package for her role as a supervisor representing the shareholders will not be specified in the service contract. The emoluments for supervisors will be proposed by the Supervisory Committee. When discussing the remuneration of an individual supervisor, the Supervisory Committee will take into account factors including the remuneration practices of comparable companies, the time commitment and responsibilities required, and the employment conditions of other positions within the Company and its subsidiaries. Ms. Liu's remuneration, once determined, will be subject to approval at the Company's general meeting.

As at the date of this announcement, save as disclosed, Ms. Liu: (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) has no other major appointment or professional qualification; (iii) has no interest and is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); (iv) has no relationship with any other Directors, Supervisors, senior management or substantial or controlling shareholders; and (v) there is no other matter in relation to the proposed appointment of Ms. Liu that needs to be brought to the attention of the shareholders or the Stock Exchange of Hong Kong Limited, and there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

The proposed appointment of Ms. Liu as a supervisor representing shareholders is subject to the approval of the shareholders by way of ordinary resolution at a general meeting of the Company. A circular containing, among other things, details of the above proposed appointment and a notice of the general meeting will be despatched to the shareholders as soon as practicable.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 24 December 2024

As at the date of this announcement, the Board comprises Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.